Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Allison Perrin"'
Autor:
Charles Wellman, Stephen P Truocchio, Thomas G. Beach, Ian Kennedy, Allison Perrin, A Study Investigators, Anupa Arora, Tricia Locascio, Andrew Siderowf, Milos D. Ikonomovic, Sudeepti Southekal, William W. Seeley, David J. Irwin, Michael D. Devous, Misty Daniel, Marybeth Devine, Mark A. Mintun, Joseph C. Masdeu, Thomas S. Harris, Val J. Lowe, Stephen Salloway, Matthew Flitter, Geidy E. Serrano, Michael J. Pontecorvo, Patricia Aldea, Abhinay D. Joshi, Adam S. Fleisher, Thomas J. Montine, Michael Navitsky, Craig Curtis, Ming Lu
Publikováno v:
JAMA Neurol
IMPORTANCE: Positron emission tomography (PET) may increase the diagnostic accuracy and confirm the underlying neuropathologic changes of Alzheimer disease (AD). OBJECTIVE: To determine the accuracy of antemortem [(18)F]flortaucipir PET images for pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91c9727057efeb248a3019f4faa25d3b
https://doi.org/10.1001/jamaneurol.2020.0528
https://doi.org/10.1001/jamaneurol.2020.0528
Autor:
M. Fernanda López, Allison Perrin, David Valcárcel, María Eva Mingot, Vicente Vicente Garcia, Ignasi Campos Tapias
Publikováno v:
Medicina Clínica (English Edition). 144:389-396
Background and objective Romiplostim, a thrombopoietin-receptor agonist, is approved for second-line use in idiopathic thrombocytopenic purpura (ITP) patients where surgery is contraindicated. Anti-CD20 rituximab, an immunosuppressant, is currently u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::416a40bc89ccdd69e20059ff7d447c14
https://doi.org/10.1016/j.medcle.2015.11.026
https://doi.org/10.1016/j.medcle.2015.11.026
Autor:
David Valcárcel, Vicente Vicente Garcia, Ignasi Campos Tapias, María Eva Mingot, M. Fernanda López, Allison Perrin
Publikováno v:
Medicina Clínica. 144:389-396
Resumen Fundamento y objetivo Romiplostim, agonista del receptor de la trombopoyetina, esta aprobado para el tratamiento de segunda linea en pacientes con trombocitopenia inmune primaria (PTI). El tratamiento con rituximab no es infrecuente, aunque e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::862f6774b8df797144cbcc62e214fb24
https://doi.org/10.1016/j.medcli.2013.11.035
https://doi.org/10.1016/j.medcli.2013.11.035
Autor:
Kenneth W. Culver, Louis P. Garrison, Roman Casciano, Xufang Wang, Magdaliz Gorritz, Zhimei Liu, A Chua, Allison Perrin, Sumanta K. Pal, Steven Sherman
Publikováno v:
Journal of Medical Economics. 18:200-209
Everolimus and axitinib are approved in the US to treat patients with advanced renal cell carcinoma (RCC) after failure on sunitinib or sorafenib, and one prior systemic therapy (e.g., sunitinib), respectively. Two indirect comparisons performed to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ea6cd86bdcd640a126e390671bac732
https://doi.org/10.3111/13696998.2014.985789
https://doi.org/10.3111/13696998.2014.985789
Autor:
Roman Casciano, Louis P. Garrison, Zhimei Liu, Xufang Wang, Allison Perrin, Maruit Chulikavit
Publikováno v:
Journal of medical economics. 15
Everolimus (Afinitor) and sunitinib (Sutent) were recently approved to treat patients with advanced, progressive pancreatic neuroendocrine tumors (pNETs). (Afinitor is a registered trademark of Novartis Pharmaceuticals Corporation, East Hanover, NJ,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7020c8f08723447493d721f72615ac90
https://pubmed.ncbi.nlm.nih.gov/22881362
https://pubmed.ncbi.nlm.nih.gov/22881362
Autor:
Allison Perrin, Pamela Werton Dalton
Publikováno v:
Kappa Delta Pi Record. 32:113-115
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da10a9358bf5299f4b95cbfa1f18140b
https://doi.org/10.1080/00228958.1996.10531984
https://doi.org/10.1080/00228958.1996.10531984
Autor:
Kris Grzegorzewski, Joseph B. Babigumira, Roman Casciano, Allison Perrin, Xufang Wang, Maruit Chulikavit, Zhimei Liu, Louis P. Garrison
Publikováno v:
Journal of Clinical Oncology. 30:e14525-e14525
e14525 Background: Everolimus and sunitinib were recently approved to treat patients with advanced, progressive pancreatic neuroendocrine tumors (pNETs). This analysis examined the projected cost-effectiveness of everolimus versus sunitinib in this d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76dc03cd94f3f1e1dfccdb2025a72c9f
https://doi.org/10.1200/jco.2012.30.15_suppl.e14525
https://doi.org/10.1200/jco.2012.30.15_suppl.e14525
Autor:
Roman Casciano, Maruit Chulikavit, Allison Perrin, Zhimei Liu, Xufang Wang, Joseph Babigumira, Louis P Garrison
Publikováno v:
Journal of Clinical Oncology. 30:226-226
226 Background: Everolimus and sunitinib were recently approved to treat patients with advanced, progressive pancreatic neuroendocrine tumors (pNETs). This analysis examines the projected cost-effectiveness of everolimus versus sunitinib in this sett
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b81cd4d9fe0ae8624c25d7b612dce0f
https://doi.org/10.1200/jco.2012.30.4_suppl.226
https://doi.org/10.1200/jco.2012.30.4_suppl.226